{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:24:19Z","timestamp":1790871859013,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Resistance of <jats:italic>Staphylococcus aureus<\/jats:italic> to vancomycin includes a general increase of minimal inhibitory concentrations (MIC) within the susceptible range over time (Vancomycin MIC Creep) and the presence of a subset of the bacterial population that expresses resistance (heterogeneous glycopeptide-intermediate <jats:italic>S. aureus<\/jats:italic>; hGISA). Increased MICs have been associated with adverse clinical outcomes. However, the vancomycin MIC creep is not a uniform trend suggesting the importance of regional surveys.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective analysis at a German pediatric tertiary care hospital. Isolates from 2002 to 2017 were selected which were newly identified methicillin-resistant <jats:italic>S. aureus<\/jats:italic> (MRSA) or samples from invasive methicillin-susceptible <jats:italic>S. aureus<\/jats:italic> (MSSA) or MRSA infections. Vancomycin and oxacillin MICs as well as GISA\/hGISA were measured using MIC test strips and resistance was evaluated over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 540 samples were tested, 200 from the early (2002\u20132009) and 340 from the later period (2010\u20132017). All samples were vancomycin susceptible, but the MIC was higher for the earlier samples as compared to the later ones (1.11 vs 0.99; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). 14% of the samples were hGISA, GISA strains were not detected. Again, vancomycin resistance decreased over time with 28 vs. 6% hGISA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There was no significant difference between MRSA and MSSA samples with respect to vancomycin MIC and hGISA prevalence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows a decreasing trend for both MIC values and presence of hGISA strains highlighting the importance of monitoring local susceptibilities. Vancomycin remains a first-line treatment option for suspected severe infection with Gram-positive cocci and proven infection with MRSA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02036-5","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T17:02:33Z","timestamp":1681837353000},"page":"583-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Decrease in vancomycin MICs and prevalence of hGISA in MRSA and MSSA isolates from a German pediatric tertiary care center"],"prefix":"10.1007","volume":"51","author":[{"given":"Katharina","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Meyer-Buehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"von Both","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-3761","authenticated-orcid":false,"given":"Tilmann","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"2036_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02185-7","author":"KS Ikuta","year":"2022","unstructured":"Ikuta KS, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(22)02185-7.","journal-title":"Lancet"},{"key":"2036_CR2","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1086\/491710","volume":"42 Suppl 1","author":"RN Jones","year":"2006","unstructured":"Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Diseases. 2006;42 Suppl 1:S13-24. https:\/\/doi.org\/10.1086\/491710.","journal-title":"Clin Infect Diseases."},{"key":"2036_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"2036_CR4","volume-title":"M 100. Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2022","unstructured":"CLSI. M 100. Performance standards for antimicrobial susceptibility testing. 32nd ed. New York: Clinical and Laboratory Standards Institute; 2022.","edition":"32"},{"key":"2036_CR5","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 12.0. http:\/\/www.eucast.org (2022). Accessed 15 Dec 2022."},{"key":"2036_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3410\/M4-4","volume":"4","author":"A Dhand","year":"2012","unstructured":"Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep\u2019): implications for therapy. F1000 Med Rep. 2012;4:4\u20134. https:\/\/doi.org\/10.3410\/M4-4.","journal-title":"F1000 Med Rep."},{"key":"2036_CR7","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","volume":"47","author":"C Liu","year":"2003","unstructured":"Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003;47:3040\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"2036_CR8","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1128\/AAC.00346-09","volume":"53","author":"B P\u00e9richon","year":"2009","unstructured":"P\u00e9richon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:4580\u20137. https:\/\/doi.org\/10.1128\/AAC.00346-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"2036_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Diseases. 2008;46:193\u2013200. https:\/\/doi.org\/10.1086\/524667.","journal-title":"Clin Infect Diseases."},{"key":"2036_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jmii.2015.05.013","volume":"50","author":"CN Chang","year":"2017","unstructured":"Chang CN, Lo WT, Chan MC, Yu CM, Wang CC. An investigation of vancomycin minimum inhibitory concentration creep among methicillin-resistant Staphylococcus aureus strains isolated from pediatric patients and healthy children in Northern Taiwan. J Microbiol Immunol Infect. 2017;50:362\u20139. https:\/\/doi.org\/10.1016\/j.jmii.2015.05.013.","journal-title":"J Microbiol Immunol Infect"},{"key":"2036_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jmii.2011.11.006","volume":"45","author":"YC Yeh","year":"2012","unstructured":"Yeh YC, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect. 2012;45:214\u201320. https:\/\/doi.org\/10.1016\/j.jmii.2011.11.006.","journal-title":"J Microbiol Immunol Infect"},{"key":"2036_CR12","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas G, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398\u2013402. https:\/\/doi.org\/10.1128\/JCM.42.6.2398-2402.2004.","journal-title":"J Clin Microbiol"},{"key":"2036_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ijantimicag.2007.07.011","volume":"30","author":"PC Appelbaum","year":"2007","unstructured":"Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrobial Agents. 2007;30:398\u2013408. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.07.011.","journal-title":"Int J Antimicrobial Agents"},{"key":"2036_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","volume":"24","author":"R Diaz","year":"2018","unstructured":"Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24:97\u2013104. https:\/\/doi.org\/10.1016\/j.cmi.2017.06.017.","journal-title":"Clin Microbiol Infect"},{"key":"2036_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1756-0500-6-65","volume":"6","author":"S Joana","year":"2013","unstructured":"Joana S, Pedro P, Elsa G, Filomena M. Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital. BMC Res Notes. 2013;6:65\u201365. https:\/\/doi.org\/10.1186\/1756-0500-6-65.","journal-title":"BMC Res Notes"},{"key":"2036_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.inf.0000436281.18687.0c","volume":"33","author":"JL Goldman","year":"2014","unstructured":"Goldman JL, Harrison CJ, Myers AL, Jackson MA, Selvarangan R. No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates. Pediatr Infect Disease J. 2014;33:216\u20138. https:\/\/doi.org\/10.1097\/01.inf.0000436281.18687.0c.","journal-title":"Pediatr Infect Disease J"},{"key":"2036_CR17","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1128\/jcm.00265-08","volume":"46","author":"A Yusof","year":"2008","unstructured":"Yusof A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol. 2008;46:3042\u20137. https:\/\/doi.org\/10.1128\/jcm.00265-08.","journal-title":"J Clin Microbiol"},{"key":"2036_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jac\/dkn520","volume":"63","author":"SN Leonard","year":"2009","unstructured":"Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrobial Chemotherapy. 2009;63:489\u201392. https:\/\/doi.org\/10.1093\/jac\/dkn520.","journal-title":"J Antimicrobial Chemotherapy"},{"key":"2036_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","volume":"350","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(97)07324-8.","journal-title":"Lancet"},{"key":"2036_CR20","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). (Stockholm, 2011)."},{"key":"2036_CR21","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). (Stockholm, 2015)."},{"key":"2036_CR22","unstructured":"European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe\u2014Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. (Stockholm, 2018)."},{"key":"2036_CR23","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","volume":"6","author":"DJ Diekema","year":"2019","unstructured":"Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis. 2019;6:S47\u201353. https:\/\/doi.org\/10.1093\/ofid\/ofy270.","journal-title":"Open Forum Infect Dis"},{"key":"2036_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/JCM.01128-10","volume":"49","author":"SW Satola","year":"2011","unstructured":"Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011;49:177\u201383. https:\/\/doi.org\/10.1128\/JCM.01128-10.","journal-title":"J Clin Microbiol"},{"key":"2036_CR25","doi-asserted-by":"publisher","first-page":"12689","DOI":"10.1038\/s41598-020-69058-z","volume":"10","author":"A Shariati","year":"2020","unstructured":"Shariati A, et al. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep. 2020;10:12689. https:\/\/doi.org\/10.1038\/s41598-020-69058-z.","journal-title":"Sci Rep"},{"key":"2036_CR26","doi-asserted-by":"publisher","first-page":"e0136082","DOI":"10.1371\/journal.pone.0136082","volume":"10","author":"S Zhang","year":"2015","unstructured":"Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. PLoS ONE. 2015;10:e0136082. https:\/\/doi.org\/10.1371\/journal.pone.0136082.","journal-title":"PLoS ONE"},{"key":"2036_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99\u2013139. https:\/\/doi.org\/10.1128\/CMR.00042-09.","journal-title":"Clin Microbiol Rev"},{"key":"2036_CR28","unstructured":"GERMAP. Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e. V. GERMAP 2015-Bericht \u00fcber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterin\u00e4rmedizin in Deutschland. (Rheinbach, 2016)."},{"key":"2036_CR29","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/22221751.2022.2032373","volume":"11","author":"B Wang","year":"2022","unstructured":"Wang B, et al. Methicillin-resistant Staphylococcus aureus in China: a multicentre longitudinal study and whole-genome sequencing. Emerg Microbes Infect. 2022;11:532\u201342. https:\/\/doi.org\/10.1080\/22221751.2022.2032373.","journal-title":"Emerg Microbes Infect"},{"key":"2036_CR30","doi-asserted-by":"publisher","first-page":"117863372097056","DOI":"10.1177\/1178633720970569","volume":"13","author":"CJ Ghia","year":"2020","unstructured":"Ghia CJ, Waghela S, Rambhad G. A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant Staphylococcus aureus infection in India. Infect Dis (Auckl). 2020;13:1178633720970569. https:\/\/doi.org\/10.1177\/1178633720970569.","journal-title":"Infect Dis (Auckl)"},{"key":"2036_CR31","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1172\/JCI68834","volume":"124","author":"S Gardete","year":"2014","unstructured":"Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014;124:2836\u201340. https:\/\/doi.org\/10.1172\/JCI68834.","journal-title":"J Clin Invest"},{"key":"2036_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jac\/dkt395","volume":"69","author":"CJ Chen","year":"2014","unstructured":"Chen CJ, Lin MH, Shu JC, Lu JJ. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. J Antimicrobial Chemotherapy. 2014;69:349\u201354. https:\/\/doi.org\/10.1093\/jac\/dkt395.","journal-title":"J Antimicrobial Chemotherapy"},{"key":"2036_CR33","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1073\/pnas.0609839104","volume":"104","author":"MM Mwangi","year":"2007","unstructured":"Mwangi MM, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA. 2007;104:9451\u20136. https:\/\/doi.org\/10.1073\/pnas.0609839104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2036_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/jac\/dki413","volume":"57","author":"F Garnier","year":"2006","unstructured":"Garnier F, et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrobial Chemotherapy. 2006;57:146\u20139. https:\/\/doi.org\/10.1093\/jac\/dki413.","journal-title":"J Antimicrobial Chemotherapy"},{"key":"2036_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1128\/AAC.48.3.1024-1027.2004","volume":"48","author":"I Verdier","year":"2004","unstructured":"Verdier I, et al. Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrobial Agents Chemotherapy. 2004;48:1024\u20137. https:\/\/doi.org\/10.1128\/AAC.48.3.1024-1027.2004.","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"2036_CR36","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90:269\u201381.","journal-title":"Yale J Biol Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:39:08Z","timestamp":1684867148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2036"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02036-5","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the ethics committee of the LMU Munich (ID 21-0334).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}